NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 319 filers reported holding NOVOCURE LTD in Q3 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $888,148 | +12.1% | 14,770 | +36.7% | 0.00% | 0.0% |
| Q4 2022 | $792,473 | -22.6% | 10,804 | -19.8% | 0.00% | 0.0% |
| Q3 2022 | $1,024,000 | +32.5% | 13,474 | +21.1% | 0.00% | 0.0% |
| Q2 2022 | $773,000 | +96.7% | 11,127 | +134.3% | 0.00% | – |
| Q1 2022 | $393,000 | +10.4% | 4,750 | +0.1% | 0.00% | – |
| Q4 2021 | $356,000 | -35.4% | 4,747 | 0.0% | 0.00% | – |
| Q3 2021 | $551,000 | -75.5% | 4,747 | -53.1% | 0.00% | -100.0% |
| Q2 2021 | $2,245,000 | +42.3% | 10,123 | -15.2% | 0.00% | +100.0% |
| Q1 2021 | $1,578,000 | -77.7% | 11,935 | -70.8% | 0.00% | -83.3% |
| Q4 2020 | $7,073,000 | +281.3% | 40,875 | +145.3% | 0.01% | +200.0% |
| Q3 2020 | $1,855,000 | +10.6% | 16,664 | -41.1% | 0.00% | 0.0% |
| Q2 2020 | $1,677,000 | -50.6% | 28,284 | -43.8% | 0.00% | -50.0% |
| Q1 2020 | $3,392,000 | – | 50,369 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |